Vetoquinol : 2023 result in line - No indication for 2024 - No immediate M&A announcement to be expected
>Underlying operating profit excl. GW in line at 16.3% of sales - Vétoquinol published EBITDA of € 113m (-4.3%), a contributory underlying operating profit of € 85m (-13.7%) and net profit of € 55.6m (+15.7% / consensus: € 55m). At end-2023, the net cash position stood at € 130m vs € 76m at end-2022. A dividend of € 0.85/share (vs. € 0.8 in 2022) is to be proposed. No guidance.No indication as to Q1 trends or guidance: little reason to change our estimat...V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.